DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1
The following criteria need to be met by your severe asthma patients:1
Severe asthma patients require treatments that will address their Type 2 patient profile
Illustrative patient profiles. Not actual patients.
EOS, eosinophils; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; IL, interleukin.